Verici Dx plc,today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.
Among older men with prostate cancer, an organ transplant is associated with higher overall mortality, but not prostate cancer-specific mortality (PCSM)